Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Viewpoint - Verastem Oncology has granted stock options to nine new employees as part of its strategy to attract talent in the biopharmaceutical sector focused on RAS/MAPK pathway-driven cancers [1] Group 1: Company Actions - The company announced the grant of stock options to purchase 138,000 shares of its common stock [1] - The stock options were awarded under the Nasdaq inducement grant exception, which is designed to incentivize new employees [1] - This action aligns with Nasdaq Listing Rule 5635(c), indicating compliance with regulatory requirements for employee compensation [1]